Otsuka Holdings 2021 Investor Relations Presentation

Otsuka Holdings presents mid-year progress on its 3rd Medium-Term Management plan, reporting upward revenue revision to ¥1.48T driven by pharmaceutical and nutraceutical growth drivers offsetting co-promotion agreement expirations. The company projects business profit of ¥200B after R&D expenses and targets ROE above 6% as part of its five-year global healthcare expansion strategy.